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ABSTRACT
Pigment epithelial derived factor (PEDF) is a secreted glycoprotein that is a 
non-inhibitory member of the serine protease inhibitor (serpin) family. PEDF exhibits 
multiple biological properties including neuroprotective, anti-angiogenic, and immune-
modulating. Interestingly, PEDF exerts the inhibitory effects in cancers derived from 
certain tissues, including prostatic, ovarian, and pancreatic carcinomas. The current 
study aimed to elucidate its role in colorectal cancer development. PEDF expression 
in human colorectal cancer tissue was assessed using quantitative polymerase chain 
reaction (qPCR) and immunohistochemical staining (IHC). The effect of treatment with 
recombinant PEDF on cellular function was examined using in vitro functional assays. 
PEDF expression was downregulated in colorectal cancer cell tissue. Treatment with 
recombinant PEDF resulted in significant decreases in the rate of colorectal cancer cell 
migration and invasion and an increase in cellular adhesion in colorectal cancer cell 
lines examined. These results indicate that upregulation of PEDF expression may serve 
as a new strategy for further investigation of therapeutic relevance to the prevention 
of the metastatic spread of colorectal cancer.
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INTRODUCTION
Pigment epithelium-derived factor (PEDF), 
also known as early population double level cDNA-1 
(EPC1), is a 50 kDa secreted glycoprotein. It was first 
identified when Tombran-Tink’s group were studying 
human retinal cell development. They found a factor 
that was secreted by the human foetal retinal pigment 
epithelial cells and showed it to be a potent neurite 
promoting factor [1]. Subsequently, PEDF was found to 
be a member of the non-inhibitory serpin gene family [2]. 
The gene encoding PEDF (SERPINF1) is localised to the 
chromosome 17p13.1 [3]. There is evidence that PEDF is 
pleiotropic with multiple biological properties including 
neuroprotective, anti-tumorigenic and immune-modulating 
[4–5] and has been shown to be one of the most potent 
endogenous inhibitors of angiogenesis, more so than 
angiostatin, endostatin, and thrombospondin-1 [6–7]. 
PEDF exerts anti-angiogenic activities by 
arresting endothelial cell proliferation and migration, 
an activity which has been shown to occur even in 
the presence of vascular endothelial growth factor 
(VEGF) [6, 8–9]. The mechanisms of action appear to 
be multifactorial; suggested underlying mechanisms of 
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PEDF biological effects on endothelial cells involve a 
complex cross-talk between the signal events triggered 
by both pro-angiogenic and anti-angiogenic molecules 
[10]. 
PEDF expression has been found to be lower in 
solid tumour tissue when compared to normal tissue from 
the same organ [11–16], suggesting that loss of PEDF 
expression may play a crucial role in tumorigenesis. 
Previous studies have also demonstrated that PEDF 
expression is downregulated with worsening prognostic 
factors in a range of cancers [11–12, 15, 17–20] and that 
treatment with recombinant PEDF has shown some benefit 
in cellular functional models [14, 19, 21–27], likely due, 
in part, to PEDF inhibiting aberrant angiogenesis, which 
leads to normalisation of healthy vasculature.
However, the evidence investigating the role of 
PEDF in colorectal cell line function has been limited. 
The current study examined the expression of PEDF in 
colorectal cancer tissue and its effect on in vitro cellular 
function of colorectal cancer cells. 
RESULTS
Low expression of PEDF mRNA in colorectal 
cancer tissues
Expression screening for PEDF was performed 
using both colorectal cancer tissue samples obtained from 
the clinical cohort and colorectal cancer cell lines. PEDF 
expression was lower in all the colorectal cancer cell lines 
when compared to the CCD-33C0 colorectal fibroblast 
cell line, used as a positive control (Figure 1). On 
transcript analysis, mRNA expression of PEDF was lower 
in colorectal tumour tissue when compared to matched 
normal colorectal tissue from colorectal cancer patients 
(Table 1). On IHC staining highest expression of PEDF 
was seen within smooth muscle, endothelial cells and 
fibroblasts (Figure 2). There was some slight cytoplasmic 
staining seen within cancer adjacent and normal colorectal 
tissue. However, there was reduced expression overall.
Association of PEDF transcript levels with 
clinical and histopathological features of 
colorectal cancer
On transcript analysis, PEDF was more highly 
expressed in females with colorectal cancer within this 
cohort when compared to males with colorectal cancer 
(p = 0.01), and in rectal tumours compared with colonic 
tumours (p < 0.001) (Table 1). Whilst there was an obvious 
decline in mRNA expression of PEDF with worsening 
tumour grade, this trend was not found to be significant 
(p = 0.187). No other demographic or clinicopathological 
association were found to be statistically significant. 
Unfortunately, survival data was not available due to the 
short follow-up period of this cohort. 
On IHC, tumour expression of PEDF was 
more pronounced in well-differentiated mucinous 
adenocarcinomas when compared to poorly differentiated 
mucinous adenocarcinomas and all grades of 
adenocarcinoma (Figure 2). There was a significant 
decrease in expression with worsening tumour grade in 
both adenocarcinomas and mucinous adenocarcinomas (p 
= 0.008 and p < 0.001, respectively), while there was no 
difference seen in expression in tumour location (colon vs. 
rectum), Dukes Stage or TNM Stage. 
Effect of PEDF on cellular function in colorectal 
cancer cells
There was no statistically significant difference 
seen in both cellular growth and invasion in either 
Figure 1: Transcript expression levels in PEDF in colorectal cell lines. Control = Nuclease free water and all gels were run with 
a molecular weight marker used to identify band sizes. 
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Table 1: Correlation between PEDF expression and clinical parameters in colorectal cohort 
N Median transcript copy number IQR P value
Tumour
Normal matched tissue
406
209
3.64 × 10–5
1.05 × 10–3
1.05 × 10−9–4.40 × 10−3
6.84 × 10−9–4.18 × 10−2 <0.001*
Female
Male
185
221
1.54 × 10–4
1.51 × 10–5
3.95 × 10−8–1.02 × 10−2
2.52 × 10−10–2.36 × 10−3 0.01*
Aged 64 years or younger
Aged 65 years or older
163
184
8.78 × 10–6
1.04 × 10–6
1.17 × 10−12−3.46 × 10−3
1.17 × 10−12−1.36 × 10−3 0.645
Female aged 64 years or younger
Male aged 64 years or younger
75
88
1.08 × 10–5
4.39 × 10–6
1.17 × 10−12− 4.18 × 10−3
2.45 × 10−12−1.44 × 10−3 0.729
Female aged 65 years or older
Male aged 65 years or older
84
100
1.47 × 10–5
5.63 × 10–7
1.17 × 1012–2.29 × 10−3
1.17 × 10−12–7.25 × 10−4 0.107
Smoker
Non-smoker
95
239
1.78 × 10–5
6.44 × 10–5
8.34 × 10−11–3.02 × 10−3
1.31 × 10−10–3.92 × 107 0.70
History of other cancers
No history of other cancers
17
375
4.02 × 10–5
5.32 × 10–5
6.54 × 10−7–2.79 × 10−3
9.62 × 10−10–4.50 × 10−3 0.617
Family history of colorectal cancer
No family history of colorectal cancer
47
344
1.85 × 10–5
6.93 × 10–5
1.69 × 10−1 0–1.15 × 10−3
4.09 × 10−9–5.25 × 10−3 0.382
Tumour location
         Colon
         Rectum
263
143
2.91 × 10–6
1.25 × 10–4
5.00 × 10−14–4.78 × 10−3
4.44 × 10−6–3.40 × 10−3 <0.001*
Tumour differentiation
          Well differentiation
          Moderately differentiation
          Poorly differentiation
84
231
37
1.31 × 10–4
2.49 × 10–5
9.69 × 10–7
3.36 × 10−7–4.00 × 10−3
1.97 × 10−10–3.31 × 10−3
1.31 × 10−11–1.83 × 10−3 0.187 
Tumour type
          Adenocarcinoma
          Mucinous adenocarcinoma
307
49
6.44 × 10–5
4.92 × 10–5
9.62 × 10−10–3.67 × 10−3
4.45 × 10−10–2.41 × 10−3 0.98
Duke’s stage
          A
          B
          C
          D
22
170
156
30
1.94 × 10–4
1.63 × 10–5
1.29 × 10–4
5.12 × 10–5
3.17 × 10−6–5.03 × 10−3
4.78 × 10−11–3.33 × 10−3
2.45 × 10−8–6.66 × 10−3
2.24 × 10−9–2.25 × 10−3 0.16
Pathological T stage
          T1
          T2
          T3
          T4
0
34
201
148
1.65 × 10–4
2.66 × 10–5
5.78 × 10–5
3.09 × 10−7–4.37 × 10−3
3.55 × 10−10–2.51 × 10−3
1.50 × 10−10–7.76 × 10−3 0.45
No nodal involvement
Nodal involvement
201
181
2.77 × 10–5
7.30 × 10–5
2.25 × 10−10–3.46 × 10−3
7.21 × 10−9–5.33 × 10−3 0.23
No metastatic disease
Metastatic disease
273
31
6.04 × 10–5
1.45 × 10–5
9.42 × 10−11–3.69 × 10−3
1.09 × 10−9–2.11 × 10−3 0.54
Radical surgery
Palliative surgery
341
45
6.48 × 10–5
1.51 × 10–5
4.09 × 10−9–4.42 × 10−3
1.50 × 10−12–5.33 × 10−3 0.54
*p ≤ 0.05.
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Figure 2: Representative immunohistochemistry images for (A) well differentiated adenocarcinoma (B) poorly differentiated 
adenocarcinoma (C) well differentiated mucinous adenocarcinoma (D) poorly differentiated mucinous adenocarcinoma (E) normal 
colorectal tissue samples. Red arrow shows cytoplasmic tumour staining. ×40 (L) and ×200 (R) magnification used. Scale bar represents 
500 µm (L) and 100 µm (R).
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HT115 or HRT-18 cell line comparing control in the 
presence of varying concentrations of rhPEDF. There 
was a statistically significant increase in the attachment 
of HT115 cells with the treatment of rhPEDF (100 ng/ml) 
when compared to the control (p = 0.003). However, 
this significant increase was not observed with 10 ng/ml 
or 50 ng/ml treatment doses of rhPEDF (Figure 3). 
No difference was demonstrated in the attachment of 
HRT-18 cells with the treatment of rhPEDF compared 
to the control. There was a statistically significant 
decrease in HT115 migration rate, evident for both 
50 ng/ml and 100 ng/ml rhPEDF treatment doses 
(p = 0.007 and p < 0.001, respectively), when compared 
to untreated HT115 cells and 10 ng/ml rhPEDF treatment 
dose (Figure 4). A similar effect was demonstrated in 
the HRT-18 cell line; a statistically significant decrease 
in HRT-18 migration rate, was evident for all doses of 
rhPEDF compared to untreated HRT-18 cells. (rhPEDF 
10 ng/ml vs control p = 0.002, rhPEDF 50 ng/ml 
p < 0.001, rhPEDF 100 ng/ml p < 0.001) (Figure 4). 
DISCUSSION
The results of this study demonstrate that PEDF 
mRNA expression was lower in colorectal cancer cell lines 
when compared to normal colorectal fibroblasts and in 
colorectal cancer tissue compared to normal tissue. These 
findings support those of Wågsäter et al. (2010) and Ji et 
al. (2013), who reported a significant reduction in serum 
PEDF levels in colorectal cancer patients compared to 
healthy controls [28–29]. 
Interestingly, mRNA expression of PEDF was 
observed to be higher in female colorectal cancer patients 
when compared to male colorectal cancer patients. This 
is contrary to both Yamagishi et al. (2006) and Wågsäter 
et al. (2010) who established that plasma samples from 
healthy male controls had higher levels of PEDF when 
compared to healthy female controls [28, 30], however a 
similar finding in colorectal cancer patients was either not 
assessed or demonstrated, in the respective studies. Other 
studies evaluating PEDF expression in other solid tumours 
did not display significance difference between genders 
[18, 31]. There is evidence to support a survival advantage 
in younger females compared to younger males, but with 
an opposite pattern in older patients [32–34]. One of the 
main reasons suggested for this effect is the favourable 
effect of endogenous female sex hormones [35]. However, 
it may be plausible that the gender difference in expression 
of PEDF may be responsible for the survival difference 
seen. In our cohort, we found no difference in PEDF 
expression comparing both genders in age groups 64 years 
or less and 65 years and over (p = 0.729 and p = 0.107, 
respectively).
Rectal tumour tissue appeared to express higher 
mRNA levels of PEDF when compared to colonic tumour 
tissue. Díaz et al. (2008) detected a similar difference with 
higher mRNA expression of PEDF in tissue from rectal 
tumours when compared to tissue from colonic tumour 
[36]. Cai et al. (2006b) found conflicting results on a 
cellular level with stronger PEDF expression in HT115 
colonic adenocarcinoma cell line and weaker expression in 
HRT-18 rectal adenocarcinoma cell line [11], however our 
Figure 3: (A) Impact of rhPEDF on cellular attachment in HT115 cells. Mean values of 3 independent repeats are shown. Error bars 
represent SEM. (B) Impact of rhPEDF on cellular attachment in HRT-18 cells. Median values and IQR of 3 independent repeats are shown. 
Error bars represent 95% confidence intervals. Absorbance × 10–2 (540 nm) readings used as a marker of cellular attachment, in response 
to varying concentrations of rhPEDF. *p < 0.05.
Oncotarget19197www.oncotarget.com
results showed little difference in the expression of these 
two cell lines and therefore there may be other factors in 
these cell lines that may be responsible for the expression 
levels shown, such as such as tumour grading or stage.
Mucinous adenocarcinoma tissue showed 
more positive tumour expression when compared to 
adenocarcinoma tissue on immunohistochemical staining, 
which is consistent with work from Ji et al. (2013) where 
patients with mucinous adenocarcinoma displayed higher 
PEDF plasma levels than adenocarcinoma patients [29]. 
This is perhaps a slightly surprising result, as mucinous 
adenocarcinoma of the colon or rectum is well recognised 
to have a poorer survival rate when compared to non-
mucinous adenocarcinoma [37] and hence there must 
be other influences, yet to be identified, that are specific 
to mucin-producing tumours that are responsible for the 
higher expression levels of PEDF.
The most frequent cause of mortality from colorectal 
cancer is related to the effects of metastatic spread, and 
therefore treatments aimed at its prevention may prove 
highly beneficial for the long-term survival of colorectal 
cancer patients. Tumour metastasis depends on several 
cancer cell characteristics including cellular proliferation, 
adhesion, invasion and migration, and hence the capability 
to adapt to in vivo environments and outcompete with 
normal cells for resources necessary for survival. To 
date, the exact mechanisms of PEDF on colorectal cancer 
metastases remain poorly understood. 
In this study, treatment with rhPEDF appeared to 
significantly decrease the rate of cellular migration. To 
date, the effect of rhPEDF on cellular function has not 
been studied in colorectal cell lines, but has been reported 
in a number of other solid tumours. Hong et al. (2014) 
reported a significant decrease in both breast cancer cell 
migration and invasion, and found that PEDF inhibited 
breast cancer cell migration and invasion by down-
regulating fibronectin and subsequent MMP2/MMP9 
reduction via p-ERK and p-AKT signalling pathways [22]. 
Correspondingly, Tan et al. (2010) found a 20% decrease 
in cellular invasion in PEDF treated chondrosarcoma 
cell when compared to control cells [27]. These findings 
support our results presented in this study. 
In the adhesion studies presented in this study, 
treatment with rhPEDF resulted in an increase in cellular 
attachment. Tan et al. (2010) found a similar finding when 
examining chondrosarcoma cells [27]. Increased adhesion 
certainly presents a beneficial effect in the prevention of 
metastatic progression, by contributing to a decreased 
ability for the cancer cells to invade and migrate. 
In conclusion, our results confirmed that PEDF 
expression was higher in normal colorectal tissue and 
cells compared to cancer tissue and cells and that PEDF 
administration confers an inhibitory effect on the migration 
and invasion of colorectal cancer cells. Future studies 
should examine the possible reasons behind a difference 
in PEDF expression patterns between the genders and 
tumour location and assess cellular function on a range 
of colorectal cancer cell lines (including metastatic and 
mucinous adenocarcinoma) and to explore the effect of 
cellular function in in vivo models using colorectal tumour 
xenografts within animal models.  
MATERIALS AND METHODS
Cell culture 
Human colorectal cancer cell lines RKO, COLO-
201, LSI74T and colorectal fibroblast cell line CCD-33C0 
were purchased from American Type Culture Collection 
(ATCC) (Rockville, Maryland, USA). Human colorectal 
cancer cell lines HT115, HRT-18 were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). The cells were 
Figure 4: (A) Impact of rhPEDF on HT115 cellular migration assessed through scratch migration assay. (B) Impact of rhPEDF on HRT-
18 cellular migration assessed through scratch migration assay. Cumulative distance travelled following scratch is shown and taken as 
representative of migration in cells compared to control and varying doses of rhPEDF.  Mean values of 3 independent repeats are shown. 
Error bars represent SEM. *p < 0.05  **p < 0.001.
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maintained in Dulbecco’s modified Eagle’s medium 
(DMEM)-F12 medium supplemented with 10% foetal 
calf serum and antibiotics. Polyclonal rabbit anti-PEDF 
was obtained from Santa Cruz Biotechnology Inc. (Santa 
Cruz, Texas, USA). Recombinant PEDF (rhPEDF) was 
purchased from R&D Systems Europe Ltd (Abingdon, 
Oxfordshire, UK) and cellular functional assays were 
performed at doses of 10 ng/ml, 50 ng/ml and 100 ng/
ml versus control medium. HT115 and HRT-18 were used 
as representative colorectal cancer cell lines for cellular 
functional assays. Unless otherwise stated, other materials 
and reagents were purchased from Sigma-Aldrich Ltd 
(Poole, Dorset, UK). 
Collection of colorectal tissue samples
Colorectal cancer tissues (n = 406) and normal 
matched colorectal tissue (n = 209) were collected during 
surgery, and stored at −80° C until use and used for 
transcript analysis. Histopathological details were obtained 
from pathological reports. Ethical approval was obtained 
from Beijing Friendship Hospital, China and consent 
received from all patients included in the cohort. Colonic 
cancer tissue microarray (T054b) and rectal cancer tissue 
microarray (RE961) purchased from US Biomax Inc. 
(Rockville, USA) were used for immunohistochemical 
staining, and these microarrays included normal tissue 
and cancer adjacent normal tissue. All specimens were 
registered and stored according to Human Tissue Act 
regulations. 
RNA extraction, reverse transcription 
polymerase chain reaction (RT-PCR) and 
quantitative PCR
RNA isolation was performed using TRI reagent®. 
RNA concentration was determined using a UV 
Spectrophotometer (WPA UV 1101: Biotech Photometer, 
Cambridge, UK). Reverse transcription was performed 
using GoTaq Green master mix (Promega, Madison, USA) 
with 500ng of RNA with each RT reaction. The quality of 
cDNA was verified by examining a housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Conventional PCR was carried out using primers for 
PEDF (Table 2). The conditions for PCR were: 94° C 
for 5 minutes, then 34 cycles of 94° C for 30 seconds, 
55° C for 30 seconds, 72° C for 40 seconds, followed by 
a final extension at 72° C for 10 minutes. Visualisation 
of products took place on 0.8% agarose gel using SYBR 
safe DNA gel stain (Invitrogen, Manchester, UK). PEDF 
transcript levels in the colorectal tissue specimens were 
determined using real-time qPCR, using Amplifluor™ 
technology as described before [37]. In brief, the 
ampliflour probe consists of a 3′ region specific to the 
Z-sequence (ACTGAACCTGACCGTACA) present 
on the target specific primers and a 5′ hairpin structure 
labelled with a flourophore [38]. The flourophore hairpin 
structure is linked to an acceptor moiety and therefore 
acts as a fluorescence quencher preventing any signal 
from being detected. During the qPCR reaction, the 
uniprobe (Millipore, Watford, UK) becomes incorporated 
and acts as a template for DNA polymerisation, in which 
DNA polymerase uses its 5′-3′ exonuclease activity to 
degrade and unfold the hairpin structure. This disrupts 
the energy transfer between the quencher and flourophore 
and results in sufficient fluorescence to be emitted and 
detected. The fluorescent signal emitted during each cycle 
is directly correlated to the amount of DNA that has been 
amplified. Pairs of qPCR primers were designed using 
Beacon Designer™ software (PREMIER Biosoft, Palo 
Alto, California, USA) as discussed in Table 2, but with 
the additional Z sequence added to the antisense primer, 
complimentary to the universal Z probe (Intergen Inc., 
Oxford, UK). Results are displayed as the number of 
transcripts/ml based on an internal standard Podoplanin 
(PDPL). All samples were made with a known dilution 
series of PDPL transcript/ml against the unknown 
samples, and they were subjected to the same conditions. 
This generated a standard curve from which transcript 
expression of the unknown samples were calculated. This 
same principal applied to the expression of GAPDH to 
ensure sample normalisation. An iCyclerIQ thermocycler 
(Bio-Rad Laboratories, Hemel Hampstead, UK) was 
used to perform the reaction, with an optical unit that 
allows real-time detection of 96 reactions. The conditions 
were: 94° C for 5 minutes, then 100 cycles of 94° C for 
10 seconds, 55° C for 35 seconds, followed by a final 
extension of 72° C for 10 seconds. 
Immunohistochemical staining of tissues
Immunohistochemistry was performed using Vector 
ABC kit (Vector Laboratories, Burlingame, California, 
USA) as described previously [39]. The cryosections were 
air-dried and fixed in acetone prior to rehydration with Tris-
buffered saline buffer. Incubation with a blocking reagent 
(10 mls of Tris-buffered saline buffer with 0.1% bovine 
serum albumin and 10% horse serum) was performed for 
1 hour in a humidified box, followed by incubation with 
the primary antibody to PEDF (1:50 dilution) for a further 
hour. Following washing, sections were incubated with 
the ABC biotinylated secondary antibody for 30 minutes. 
Washing was repeated with further incubation of the ABC 
reagent for 30 minutes. ABC reagent used consisted of 5 
ml of blocking reagent with 100 µl of reagent A and 100 µl 
of reagent B (Cat no. PK-6200; Vectastain Universal Elite 
ABC Kit, Vector Laboratories, Burlingame, California, 
USA). Washing was once again repeated, and sections 
were subsequently developed in DAB substrate for 5 
minutes and then counterstained with Hematoxylin Gill’s 
Formula (Vector Laboratories, Burlingame, California, 
USA) for 2 minutes followed by dehydration in ethanol, 
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clearing in xylene and mounting in DPX. The samples 
were visualised using a Leica DM 1000 LED microscope 
(Leica Microsystems Ltd, Milton Keynes, UK) at ×100 
magnification. Software used to capture images was 
LAS EZ (Leica Application Suite, Milton Keynes, UK). 
All specimens were analysed anonymously. Details of 
demographical and clinicopathological associations were 
provided during experimental data analysis.
In vitro cell growth assay
The standard technique used has been previously 
described [40]. Cells were seeded into 96-well plates at a 
seeding density of 3 × 103 cells per well. Cell growth was 
measured after 1,3 and 5 days. Crystal violet cell staining 
was performed and analysis of absorbance was performed 
at 540 nm using a spectrophotometer (BioTek™ EL × 
800™; BioTek). 
In vitro tumour cell matrigel adhesion assay
The standard technique used has been previously 
described [41]. Cells were seeded into Matrigel-coated 
(BD Matrigel™ Basement Membrane Matrix; BD 
Bioscience, Oxford, UK) wells (5 µg/well) at a seeding 
density of 4.5 × 104 cells per well. Following 45 minutes 
of incubation, non-adherent cells were washed off using 
balanced salt solution buffer. The remaining cells were 
fixed, stained with Crystal violet and then analysed using 
a spectrophotometer at 540 nm. 
In vitro scratch migration assay
As previously described [42], cells were seeded into 
a 24-well plate at a seeding density of 3 × 105 cells per 
well, and were incubated for 24 hours. After incubation, 
a straight-line scratch was made to the cellular monolayer 
using the end of a sharpened 200 µl pipette tip down the 
midpoint of each well. The medium was then removed 
from the plates carefully and replaced with 500 µl of either 
treatment or control. The analysis was performed using 
EVOS cell imaging system (Life Technologies, Paisley, 
UK) and images were captured every 60 minutes for a 
total of 6 hours. Migration distances were measured using 
Image-J software (National Institutes of Health, USA). 
In vitro cellular invasion assay
The methods used to determine the invasive ability 
of the cells in this study have been previously described 
[43]. Transwell inserts with 8 µm pores were coated 
with 50 µg of Matrigel™ and air-dried. After rehydrated, 
3 × 104 cells were seeded per well. Following 72 hours, the 
cells that migrated through the matrix to the underside of the 
insert were fixed and stained. The dye was solubilised using 
acetic acid and analysed using a spectrophotometer at 540 nm 
with absorbance levels as a marker of cell density presented.
Statistical analysis
Statistical analysis was performed using Sigma plot 
11.0 statistical software (Systat Software Inc.). Student 
T-test was used for parametric data and Mann–Whitney 
U test for non-parametric data, where two variables were 
present. The significance of associations between PEDF 
mRNA levels and clinicopathological variables and 
for functional cellular assays (except migration assays) 
were assessed by Kruskal–Wallis one-way analysis of 
variance on ranks test, and pairwise multiple comparison 
procedure (Dunn’s method). Two-way analysis of variance 
was performed for migration assay data. Parametric data 
were presented as mean values with error bars depicting 
standard error of the mean (SEM). Non-parametric data 
was presented, were possible as boxplots, with median 
values and interquartile range (IQR), with error bars 
depicting 95% confidence intervals. Differences were 
considered to be statistically significant at p ≤ 0.05.
Table 2: Primers for conventional RT-PCR and real time qPCR
Gene Primer name Primer Sequence (5′-3′)
PEDF SERPINF1 F50 ATCCTTTCTTCAAAGTCCCC
SERPINF1 R50 ATTTTATGCGCAGCTTCTTC
PEDFF1 GGTGCTACTCCTCTGCATT
PEDFZR ACTGAACCTGACCGTACAAGAAAGGATCCTCCTCCTC
GAPDH GAPDHF8 GGCTGCTTTTAACTCTGGTA
GAPDHR8 GACTGTGGTCATGAGTCCTT
GAPDHF1 AAGGTCATCCATGACAACTT
GAPDHZR1 ACTGAACCTGACCGTACAGCCATCCACAGTCTTCTG
PDPL PDPLF8 GAATCATCGTTGTGGTTATG
PDPLZR ACTGAACCTGACCGTACACTTTCATTTGCCTATCACAT
ACTGAACCTGACCGTACA represents the Z sequence.
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factor; qPCR: quantitative polymerase chain reaction; 
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metastases staging; VEGF: vascular endothelial growth 
factor; RT-PCR: reverse transcription polymerase chain 
reaction.
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